Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
GlaxoSmithKine plc has announced today the submission of a New Drug Application to the United States Food and Drug Administration (FDA), for approval to market. Tykerb® (lapatinib ditosylate), in combination with Xeloda® (capecitabine).
The new compound is meant for the treatment of advanced metastatic HER2 (ErbB32) positive breast cancer in women who have received prior therapy, a statement read.
The FDA has already granted fast track status to the compound. To date Tykerb is an investigational drug and has yet to be given approval for marketing by any regulatory body.
Paolo Paoletti, M.D., Senior Vice President of the Oncology Medicine Development Center at GlaxoSmithKline said in a statement: “This filing is the result of many years of tremendous research and development work by the scientists at GSK. It is truly an outstanding milestone, especially for the many thousands of women who are facing the devastating effects of advanced breast cancer,”
Next weeks G8 may shine the spotlight on the USD as the global standard
The U.S. economy likely shed a further 355,000 jobs in June and the unemployment...
Cisco live 2009 website is down and nobody can access the site for the latest in...
Effective and Affordable Press Release Distribution Service
Partners  
|
© 2009 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
